Cancer Institute A national cancer institute
designated cancer center

Samuel So

Publication Details

  • Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma ANTICANCER RESEARCH Yen, Y., So, S., Rose, M., Saif, M. W., Chu, E., Liu, S., Foo, A., Jiang, Z., Su, T., Cheng, Y. 2009; 29 (10): 4083-4092

    Abstract:

    PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (16.5 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.

    View details for Web of Science ID 000271487400053

    View details for PubMedID 19846955

Stanford Medicine Resources:

Footer Links: